title: [The value of thrombolysis for the treatment of acute pulmonary embolism].
abstract: In the 1970s controlled studies in acute massive and submassive pulmonary embolism demonstrated by angiography, scintiscan and hemodynamic measurements that urokinase (UK) and streptokinase (SK) induce a more rapid dissolution of thrombotic material in the pulmonary circulation than heparin. Thousands of individuals would have been needed to prove a statistically significant reduction in the relatively low mortality (10-20%) in the study population. However, in massive pulmonary embolism with right ventricular overload, the advantage of thrombolysis is clearly evident. As confirmed by treatment series of varying size, SK and UK usually require 1-3 days for extensive clearance accompanied by impressive functional improvement. If contraindications are observed and invasive procedures avoided, the bleeding risk is acceptable. Acute severe pulmonary embolism with marked pulmonary hypertension but stable circulation should be treated with conventional doses of SK or UK for several days. In cases with unstable circulation or established shock vital improvement may be obtained by bolus injection (into pulmonary artery, right atrium or i.v.) of 2 m I.U. UK or by short i.v. infusion of 100 mg tissue plasminogen activator. Rapid reduction of pulmonary vascular resistance to a less critical value will prevent right ventricular decompensation and save time for embolectomy or subsequent conventional thrombolytic therapy.
authors.affiliation: Gerinnungs- und Fibrinolyselaboratorium, Kantonsspital Basel.
authors.forename: G A
authors.initials: GA
authors.lastname: Marbet
mesh_terms: D000208:Acute Disease; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D011655:Pulmonary Embolism / Q000188:drug therapy* / Q000503:physiopathology; D013300:Streptokinase / Q000008:administration & dosage / Q000627:therapeutic use; D015912:Thrombolytic Therapy / Q000379:methods*; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage / Q000627:therapeutic use*; D014655:Vascular Resistance / Q000187:drug effects
chemical_list: D006493:Heparin; D013300:Streptokinase; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator
vernacular_title: Der Stellenwert der Thrombolyse für die Behandlung der akuten Lungenembolie.